3 learning resources available for this topic
Alcohol withdrawal syndrome (AWS) is a potentially life-threatening condition that occurs when patients with alcohol use disorder abruptly reduce or stop drinking. Severe manifestations including seizures and delirium tremens (DTs) require urgent recognition and treatment.
Chronic alcohol exposure upregulates excitatory NMDA receptors and downregulates inhibitory GABA receptors. Abrupt cessation removes alcohol's GABA-mimetic and NMDA-antagonist effects, resulting in unopposed CNS excitation. The Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) quantifies severity. Seizures typically occur 6-48 hours after last drink; DTs peak at 48-96 hours and are characterized by autonomic instability, hyperthermia, and severe agitation.
Risk stratification uses the CIWA-Ar protocol or PAWSS score. Benzodiazepines are the cornerstone of treatment, acting on GABA receptors to suppress CNS hyperexcitability. Thiamine must be administered before glucose to prevent Wernicke's encephalopathy. Key clinical reasoning points: anticipate seizures in patients with prior withdrawal seizures or DTs, monitor for concurrent infections or metabolic derangements that can complicate the picture, and recognize that AWS can mimic or coexist with hepatic encephalopathy.
Common clinical reasoning questions about this topic
The Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) is a 10-item scale scoring nausea, tremor, diaphoresis, anxiety, agitation, perceptual disturbances, headache, and orientation. Scores guide benzodiazepine dosing in symptom-triggered protocols.
Alcohol withdrawal seizures typically occur 6-48 hours after the last drink, peaking around 24 hours. They are usually generalized tonic-clonic and brief. Prior seizure history is the strongest predictor of future seizures.
Delirium tremens (DTs) is the most severe form of alcohol withdrawal, occurring in 3-5% of patients, typically 48-96 hours after last drink. It is characterized by autonomic instability (tachycardia, hypertension, fever), severe agitation, confusion, and hallucinations, with mortality up to 5% if untreated.